Affymax Announces Promotion of Michael Holfinger
News Jul 10, 2012
Affymax, Inc. has announced the promotion of Michael Holfinger, Ph.D., to vice president, manufacturing and CMC development.
Dr. Holfinger, who has more than two decades of experience in global manufacturing services for pharmaceutical and biotechnology companies, joined Affymax in 2006 as director, process development and manufacturing.
“During his tenure at Affymax, Mike has shown impressive leadership skills and made significant contributions to our process and manufacturing development program for OMONTYS,” said John Orwin, chief executive officer of Affymax.
Orwin continued, “Looking ahead, his proven track record of overseeing complex commercial production at a global level and his intimate familiarity with the manufacturing process we have developed with our partner, Takeda, will be essential as we increase commercial production.”
Prior to joining Affymax, Dr. Holfinger held multiple positions at Pfizer, including most recently as senior manager in the API support team where he was responsible for change management, project management and technical support activities necessary to ensure an economical uninterrupted commercial supply of pharmaceutical ingredients for various products.
Prior to Pfizer, Dr. Holfinger held multiple positions within the chemical process research and development group at Pharmacia Corporation, where he was responsible for implementation of commercial processes for the manufacturing of chemical intermediates and active pharmaceutical ingredients.
From 1997-2004, he was a course instructor at the Pharmaceutical Education & Research Institute.
He earned his Ph.D. in chemical engineering from the University of Wisconsin-Madison and received a dual B.S. degree in applied science, paper science, and engineering and chemistry at Miami University.
Catalysis is common in many industries such as pharmaceutical, specialty chemicals, agriculture, polymer and over 90% of chemicals are made from catalytic processes. Researchers have reported an asymmetric reaction that uses a cationic (positively charged) catalyst to convert racemic (equal mixture of two enantiomers) substrates to asymmetric product via an intriguing reaction route,READ MORE